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Abstract
Background: People who inject drugs (PWID) are most at risk of hepatitis C virus infection in Australia. The
introduction of transient elastography (TE) (measuring hepatitis fibrosis) and direct acting antiviral medications will
likely alter the experience of living with hepatitis C. We aimed to explore positive and negative influences on
wellbeing and stress among PWID with hepatitis C.
Methods: The Treatment and Prevention (TAP) study examines the feasibility of treating hepatitis C mono-infected
PWID in community settings. Semi-structured interviews were conducted with 16 purposively recruited TAP
participants. Participants were aware of their hepatitis C seropositive status and had received fibrosis assessment
(measured by TE) prior to interview. Questions were open-ended, focusing on the impact of health status on
wellbeing and self-reported stress. Interviews were voice recorded, transcribed verbatim and thematically analysed,
guided by Mishel’s (1988) theory of Uncertainty in Illness.
Results: In line with Mishel’s theory of Uncertainty in Illness all participants reported hepatitis C-related uncertainty,
particularly mis-information or a lack of knowledge surrounding liver health and the meaning of TE results. Those
with greater fibrosis experienced an extra layer of prognostic uncertainty. Experiences of uncertainty were a key
motivation to seek treatment, which was seen as a way to regain some stability in life. Treatment completion
alleviated hepatitis C-related stress, and promoted feelings of empowerment and confidence in addressing other
life challenges.
Conclusion: TE scores seemingly provide some certainty. However, when paired with limited knowledge,
particularly among people with severe fibrosis, TE may be a source of uncertainty and increased personal stress.
This suggests the need for simple education programs and resources on liver health to minimise stress.
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Background
Hepatitis C infection remains a significant public
health concern, with an estimated 71 million people
chronically infected worldwide [1]. In Australia and
other developed countries, the sharing of injecting
equipment is the most common source of hepatitis C
exposure, placing people who inject drugs (PWID) at
greatest risk of infection [2, 3]. Persistent infection may
lead to fibrosis, liver disease, hepatocellular carcinoma,
liver transplant and extrahepatic manifestations [4, 5].
Fibrosis progression is variable, with approximately
10–20% of individuals with hepatitis C developing cirrho-
sis within 20–30 years of infection [4, 6, 7]. In Australia,
hepatitis C infection is the leading cause of liver trans-
plant, with the burden of hepatitis C liver related disease
predicted to triple by 2030 [8].
Recently, the therapeutic landscape of hepatitis C has
drastically changed. Non-invasive fibrosis assessment
tools, such as transient elastography (TE) (an ultrasound
like device which determines liver stiffness by measuring
wave velocity [9]) and highly effective interferon-free
direct acting antiviral (DAA) medications are now con-
sidered standard of care [10, 11]. These advances have
made the elimination of hepatitis C as a public health
threat a real possibility, particularly in Australia, where
DAAs are widely accessible and heavily subsidised
[12, 13]. However, such advances may also alter the
individual experience of living with hepatitis C.
The qualitative literature has long reported that diag-
nosis of a chronic illness such as hepatitis C fosters feel-
ings of fear, shock, despair, condemnation, confusion
and uncertainty [14–19]. Mishel’s 1981 theory of Uncer-
tainty in Illness [20] describes uncertainty as an ‘inability
to determine the meaning of, or predict outcomes of
illness-related events’ (p 225). This concept of Uncer-
tainty in Illness may be manifested through four forms;
1) ambiguity regarding illness state, 2) complexity
regarding treatment and system of care, 3) lack of infor-
mation received or understood, particularly around diag-
nosis and illness severity and/or 4) unpredictability of
disease course and prognosis [20, 21]. Experiences of
illness-related uncertainty may jeopardise one’s sense of
personal stability, culminating in stress [19, 20]. The
term uncertainty is used broadly in this paper to
describe the concept of Uncertainty in Illness.
Whilst the concept of uncertainty has been the focus
of research in populations of people living with Parkin-
son’s disease [22], Diabetes Mellitus [23], Cancer [24]
and Human Immunodeficiency Virus [25, 26], there are
few studies exploring uncertainty in people living with
hepatitis C [27, 28]. Bailey et al. [27] quantitatively mea-
sured uncertainty in people living with hepatitis C who
were undergoing ‘watchful and waiting’ protocol, how-
ever, did not specify participants’ injecting status.
Rhodes, Davis and Judd [28] conducted in-depth inter-
views with PWID in London and found uncertainty, as a
lack of knowledge of hepatitis C prominent, although
only 32% of this sample was hepatitis C positive.
The advent of TE to measure the degree of fibrosis
means that PWID living with hepatitis C can be more
easily made aware of their liver disease progression.
Hence, at first blush it seems reasonable to expect that
the TE score introduces an aspect of certainty into the
lives of those living with hepatitis C. DAA medication
provides the prospect of effectively being cured [12],
however, for those with pre-existing advanced liver dam-
age, considerable uncertainty about their future health
outcomes will remain. Hence, testing and treatment
advances may influence the experience of and degree of
uncertainty felt by those living with hepatitis C.
This study explores how uncertainty in the context of
TE scores and DAA treatment affects self-reported stress
in PWID living with hepatitis C. In particular, we focus
on how uncertainty in relation to degree of fibrosis and
the prospect of receiving treatment is related to stress.
Understanding sources of uncertainty in PWID living
hepatitis C may aid in developing appropriate resources
to reduce hepatitis C related stress.
Methods
Participants
Participants were recruited from the Treatment and
Prevention (TAP) study, which examines the feasibility
of treating hepatitis C mono-infected PWID in a
community-based setting [29]. All TAP participants were
eligible for qualitative interview provided they had
received a valid liver fibrosis assessment and positive
(detected) hepatitis C RNA Polymerase Chain Reaction
test, at TAP study screening between February 2015 and
August 2016. All participants had received a liver
stiffness score prior to interviews. Liver stiffness was
measured by TE (FibroScan™; Echosense, France). Partic-
ipants were recruited through a mix of stratified purpos-
ive and opportunistic sampling. Participants were
grouped as either; ‘high-level fibrosis’ (liver stiffness ≥9.5
Kpa corresponding to METAVIR stage F3/F4) or ‘low-
level fibrosis’ (liver stiffness < 9.5 Kpa or F0-F2). Initially
a purposive sample of 22 potential participants was se-
lected from TAP, stratified based on age, gender and
level of fibrosis (as recorded at trial screening). All 22
participants were contacted via telephone but only two
were available for interview (9% response rate). Of these
22 participants the majority had disconnected phone
numbers.. Consequently, all eligible TAP participants
accessing the trial field sites were sequentially invited to
participate and, if they consented, were subsequently
interviewed by the first author. Fifteen participants were
invited to participate through this method, and 14 were
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interviewed (93% response rate) including seven partici-
pants from the original purposive sample. Through both
recruitment methods a total of 16 participants were
interviewed. Participants with high-level fibrosis were
intentionally ‘over-sampled’ (the proportion of partici-
pants with high-level fibrosis in our sample does not
reflect the general population) to provide sufficient data
to compare experiences between those with high and
low-level fibrosis.
Data collection
Qualitative methodology was employed to gain a more
nuanced and in-depth understanding of liver health and
wellbeing for PWID living with hepatitis C. Semi-
structured interviewing occurred between June and
August 2016 across five Melbourne metropolitan sites.
Interviews were conducted at community health ser-
vices, needle and syringe programs or a tertiary hospital.
The interview schedule was informed by the literature
on qualitative methodology [30, 31], the research ques-
tion and discussion between co-authors. Interviews were
informal and flexible, using broad prompts such as, ‘what
are some things you find stressful at the moment?’ This
allowed participants to discuss aspects of life they be-
lieved to be impacting on their wellbeing, without being
directly asked or feeling obliged to talk about specific
factors. Follow-up prompts were on topics such as the
physical and emotional effects of hepatitis C and fibrosis
and attitudes towards fibrosis and treatment.
Interviews lasted approximately 30 min (range: 17–
46 min) and were digitally voice recorded. Participants
were reimbursed $AUD40 for their time.
Data analysis
Participant characteristics collected at TAP screening
were identified though pre-assigned unique participant
numbers and were utilised to describe the sample.
‘Employed’ included: full-time, part-time or casual
employment.
Interviews were transcribed verbatim using Microsoft
Word and VLC Media Player (v 2.2.4, VideoLAN
Organization, Paris, France). Interviewed participants
were assigned unique interview codes and any identify-
ing information was removed from transcripts to ensure
anonymity.
Transcripts were read, re-read and then analysed the-
matically using both inductive and deductive analysis.
Deductive codes were based on the four forms of Uncer-
tainty in Illness (ambiguity, complexity, lack of informa-
tion and prognostic unpredictability). Three processes of
coding were used; open, axial and thematic [30]. During
open coding each line of the transcript was assigned a
summative word or phrase. Axial coding focussed on
identifying themes from issues that emerged in the open
coding stage. This included exploring the physical and
emotional impacts of aspects of life that were frequently
mentioned. Finally, thematic coding involved under-
standing what was driving major positive and negative
impacts on stress levels and differences between fibrosis
groups. The analysis process was conducted iteratively
so themes that emerged later in analysis were applied to
earlier transcripts. Axial and thematic codes were
discussed among authors. Thematic codes were also
developed with two independent fieldworkers who regu-
larly interviewed PWID.
All participants provided informed consent and ethics
approval was received by the Monash University Human
Research Ethics Committee.
Results
Sample characteristics
Sixteen interviews were conducted. Participants were
aged between 33 and 56 years old (mean: 41 years old
±8.17 years), with most being male (n = 11, 69%).
Almost all participants were unemployed and had not
completed high school. Close to half the sample had
high-level fibrosis (n = 7, 44%). Four participants had
been hepatitis C virus (RNA) positive in the past, but
had cleared infection at the time of interview. They were
included in analysis for their unique perspective of hav-
ing recently cleared their infection either spontaneously
or through treatment.
Uncertainty: A key negative impactor on stress
Uncertainty was ubiquitous in the lives of participants
we interviewed. Issues that participants reported as
stressful consistently appeared to be shrouded in uncer-
tainty or instability, irrespective of the nature of the
issue. It was clear that many participants navigated com-
plex aspects of life with trepidation, conceding to feeling
generally “lost,” “stuck,” “jumbled up” or “helpless.”
These feelings were attributed to a range of factors, in-
cluding; illness related uncertainty due to their hepatitis
C diagnosis, stigma and discrimination, as well as fear of
transmission to others. However, themes of stigma,
discrimination and fear of transmission have been well
described in previous studies [32–35]. Hence, this paper
will focus on hepatitis C related uncertainty (ambiguity,
lack of information and prognostic unpredictability) and
stress, through the scope of TE score, liver health know-
ledge and DAA treatment.
Fibrosis related uncertainty: ambiguity and lack of
information
Most participants had been diagnosed with hepatitis C
many years prior to interview as having “non A, non B”
hepatitis or when “Hep C wasn’t even invented”, but had
only recently been told their level of fibrosis through the
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TAP study. Throughout the trial, research nurses experi-
enced in hepatitis C and working with PWID provided par-
ticipants with information and explanation of TE results.
Many participants also received consultation regarding
their hepatitis C from other healthcare providers, outside of
the TAP study. Despite the consultation with research
nurses following their liver assessment; most participants
either did not understand or missed key information re-
garding their TE results, which ignited feelings of stress.
I didn’t know anything about it, [doctors] were like:
‘liver cancer and liver all these things’ and I got really
freaked out. (P15, low-level fibrosis)
Approximately half the participants were unclear about
the true meaning of TE results, implications of the result
and how to manage their fibrosis. Participants were often
left feeling frustrated or perplexed when their perceptions
of liver health or treatment options did not align with
their doctors’, particularly with their liver specialists:
What I understood from [the liver specialist] is that a
third is damaged. Well I’m like; ‘can’t you cut a third
off?’ Just get rid of that broken bit, it’s simple for me!
Then I don’t need to live with the stress. And they’re
like; ‘it doesn’t work like that’. That doesn’t make sense
to me. (P1, high-level fibrosis)
Confusion over the significance of TE results was also
common. TAP participants with a liver stiffness above
9.5Kpa were referred to a clinical site to have their TE
test repeated and consult with a specialist clinician. One
such participant with high-level fibrosis, who had re-
ceived a TE result, specialist nurse consultation and re-
ferral to a tertiary hospital through TAP immediately
prior to our interview, seemed unaware of the meaning
of a score indicative of advanced fibrosis:
My liver was 12 something, they had to refer me,
anything over 10 she said…even though 12 wasn’t that
bad, but because it is over 10 she’s not qualified to do it,
so I have to get sent to…what’s that place called?
Somewhere to get the big scan. (P4, high-level fibrosis).
There were widespread gaps in knowledge regarding
liver health and the TE scores, most of which stemmed
from misunderstanding health professionals. This in-
duced a sense of worry and confusion.
Fibrosis related uncertainty: prognostic uncertainty and
unpredictability
All participants demonstrated a lack of knowledge about
general liver health irrespective of TE result. However,
those with more severe fibrosis expressed a greater de-
gree of worry and stress about how their fibrosis would
affect their future than those with low level fibrosis.
Those with low scores generally believed that their
degree of fibrosis did not warrant major concern. This
appeared to be due to a general lack of symptoms and
being told by a health professional that their level of
fibrosis was not ‘severe’ or ‘cirrhotic’:
I don’t really put it on my mind, that’s probably why
it’s so low. I don’t worry about it. (P13, low-level
fibrosis)
[The TE score] was alright, they said it was good. So
yeah I don’t think my hep C impacts me that much.
(P15, low-level fibrosis)
For this group the certainty of a TE score was useful in
preventing worry and stress. In contrast, participants with
high-level fibrosis expressed a persistent and palpable
worry about their liver health. These participants were
often uncertain whether their fibrosis was progressing.
This was particularly stressful for those who were not at-
tending TE appointments as regularly as recommended.
Some participants felt they no longer knew their TE score
and were fearful of becoming aware it had increased:
I’m scared to go to the fibro clinic. My brother in law
went…he has cirrhosis of the liver. I’m scared the same
thing is going to happen to me. I would like to know
my [TE] score but in a way I don't want to know. I'm
just lost at the moment. (P6, high-level fibrosis)
The not knowing of the levels, the not knowing how
serious it is. I need to know. It’s my life. This is
massive! I’ve got grandkids! (P5, high-level fibrosis).
Participants were not only stressed about the state of
their livers but seemed unsure of what was expected of
them, how to manage their fibrosis, what medical inter-
ventions were required and effective and how this would
impact their everyday life. The possibility of developing
end stage liver disease was a major concern for partici-
pants. Multiple participants exhibited a misunderstand-
ing of medical interventions for end-stage liver disease,
believing they would require dialysis (an intervention for
kidney failure):
I know [my liver] is important cause I might need a
new liver or I might need to go on dialysis. I don’t
want to end up like that. (P6, high-level fibrosis)
It’s stressful just knowing I’ve damaged my liver. I feel
depressed my body is so down, the liver’s not
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working. Not knowing if I can do anything to fix it is
just the worst, because it’s something I didn’t know I
got, and now I don’t know how to get rid of it. It’s scary
because it’s one of those things that if it collapses you
have to be on dialysis or whatever and I’ve seen the
dialysis rooms, they have to go and get their blood
cleaned, it’s quite scary. (P14, high-level fibrosis)
This degree of prognostic uncertainty, confusion and
stress was unique to those interviewed with high-level
fibrosis. These participants also frequently reported
fatigue-like symptoms such as finding it difficult to exert
themselves in the capacity they once could. This restric-
tion on daily living was often difficult to come to terms
with, especially as for many it had meant stopping work,
giving up hobbies such as bike riding and having to stop
consuming alcohol:
Because of the way my liver is, they can’t even give
you an answer of what my quality of life will actually
be when I’ve finished the Hep C tablets, whether I can
go back to work or not. (P1, high-level fibrosis)
Finding stability through treatment
Hepatitis C was often spoken of as a relatively minor
concern in the face of other medical issues, unemploy-
ment, financial difficulties, mental illnesses, drug use
and dependence, and strained personal relationships.
However, with many participants confident they will be
cured, hepatitis C was seen as the current and most
manageable hurdle.
[Clearing hepatitis C] will help in defeating the bigger
problems, because it’s like trying to get up when
you’ve got 100 bricks on ya. But then if I took half the
bricks off from the Hep C, then now I’ve got a bit
more movement and I can start taking the bricks off.
(P14, high-level fibrosis)
Not only was treatment seen as achievable but the pro-
spect of becoming ‘cured’ from hepatitis C was viewed
as “a lease on life”, a chance to “calm down”, being
“comfortable with the kids”, or “normal again”, “one less
major problem”, “evening up the playing field”, or clear-
ing “the brain fog.” Underlying these motivations was
the desire to ease the stress and uncertainty of living
with hepatitis C:
I think it will mean a lot mentally. Just the knowledge
that; ‘ahh it’s finally gone.’ I don't think about it but
I'm sure I probably do and don't realise it. Once I
know it's gone I think it will be a weight off my
shoulders. (P8, low-level fibrosis)
Relieving some of the stigma and discrimination partici-
pants felt was also a motivator to seek treatment. Partici-
pants often described no longer wanting to feel
“shameful”, “not normal” or “dirty”. One participant had
a history of working in harm reduction services and had
observed similar attitudes:
I ask people, ‘why did they feel the need to be treated?’
and a lot of them say because they felt dirty. We aren’t
dirty, we just have a virus. (P16, low-level fibrosis)
These motivations were universal across fibrosis levels.
Participants who had completed treatment described a
sense of relief from uncertainty but also a sense of
empowerment:
When I knew I had this sickness there was a fog. To
have the doctors say it was gone, it was unreal. I don’t
know how to explain it, it felt like butterflies and
flowers, I feel alive again, with purpose again and it
has motivated me to be better. (P9, high-level fibrosis)
It meant I could live again, I could do anything I
wanted and didn't have to worry. (P7, low-level
fibrosis)
When participants described their hopes about accessing
treatment, it appeared they wanted to minimise or com-
bat feelings of uncertainty. They were seeking stability in
their lives. From the narratives of participants who were
no longer living with chronic hepatitis C, treatment, ei-
ther community based (for those with low-level fibrosis)
or through tertiary hospitals (for those with high-level
fibrosis) had removed many of the hepatitis C related
uncertainties that other participants were describing.
Not only did treatment reduce the negative feelings
associated with hepatitis C and fibrosis, it generated new
positive feelings of confidence and an enhanced ability
to navigate life’s complexities.
Discussion
Amidst a rapidly changing therapeutic environment, our
study provides insight into the impact of liver health re-
lated uncertainty on self-reported stress levels in PWID
living with hepatitis C. Our study also revealed motiva-
tions for seeking and impact of new DAA treatment in
this population. There were three key findings. Firstly,
whilst TE is intended to introduce an element of
certainty into the lives of those living with hepatitis C, it
may be a source of ambiguity, lack of information prog-
nostic uncertainty and ultimately stress. Secondly, liver
health uncertainty may be heightened among those with
severe fibrosis, as the future appears more unstable,
leading to a greater degree of self-reported stress and
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anxiety. Finally, treatment facilitates a sense of certainty
and stability, which allows participants when treated to
feel a sense of empowerment, confidence and agency
over their life.
In our sample much of the TE related uncertainty was
due to limited knowledge. This is consistent with the lit-
erature reporting low levels of health literacy and hepa-
titis C knowledge among PWID living with hepatitis C,
which may cause confusion or act as a barrier to treat-
ment [16, 36, 37]. Treloar et al. [38] conducted a self-
administered survey with 132 hepatitis C positive clients
from Australian opioid substitution therapy clinics.
Consistent with our participants’ depictions of fibrosis;
the authors noted that levels of knowledge surrounding
hepatitis C disease progression were particularly low.
Glacken, Kernohan and Coates [16] conducted nine
in-depth interviews with people living with hepatitis C.
They reported diagnosis related uncertainty as arising
from a lack of clinical and prognostic knowledge, which
resulted in fear and anxiety. Nevertheless, we found such
substantial gaps in knowledge somewhat surprising
given participants’ involvement in a hepatitis C treat-
ment trial. For example, numerous participants worried
about receiving dialysis if their fibrosis were to progress
to liver failure, despite dialysis not being a treatment
option for decompensated cirrhosis. However, the
broader literature regarding uncertainty in illness sug-
gests that people often receive contradictory information
regarding chronic illness [18], do not passively accept
expert information but rather reinterpret this knowledge
through the scope of lay experiences [39] or may
encounter information overload which affects attention
and recall [19].
The finding that there was a greater degree of fibrosis
related uncertainty and thus self-reported stress among
those with more severe fibrosis has not previously been
reported, but is not surprising. The combination of
awareness of a serious degree of fibrosis, yet little clinical
or prognostic knowledge fostered anxiety around life
expectancy, disease progression and how fibrosis would
impact everyday life. It has not been explored in
hepatitis C specifically but others report a positive asso-
ciation between illness severity and uncertainty [19].
Further, quantitative studies suggest that increased
fibrosis may be associated with poorer health related
quality of life [40, 41]. Bailey et al. [27] tested the Mishel
Uncertainty in Illness Scale in 126 untreated people
living with chronic hepatitis C. A moderate level of ill-
ness uncertainty was seen in this group. Further, the
subscales (ambiguity, complexity, inconsistency and un-
predictability) were correlated with outcomes such as;
depressive symptoms, fatigue, pain and quality of life.
However, participants were not distinguished based on
disease stage.
There is currently little qualitative published work on
the impact of DAA treatment on individuals. Our find-
ings of the overwhelmingly positive psychosocial effects
of treatment are also reflected in the treatment stories
on numerous hepatitis C blogs and websites [42–44].
Our study was not without limitations. All participants
received a TE score prior to interview. However, the
time lapse between TE and interview differed between
participants, which may have influenced participants’
understanding of their fibrosis. Further, the response rate
through the first wave of recruitment was far lower (9%
compared to 93%). This is likely due to the first mode of
recruitment relying on telephone contact from a tele-
phone number unknown to participants. This is prob-
lematic as many PWID do not answer telephone calls
from unfamiliar numbers, have limited credit to return
calls, may be in contact with the justice system or
rehabilitation services and frequently change contact
information [45].
Conclusion
Despite TE seemingly providing people living with hepa-
titis C some certainty, in our study when paired with
limited knowledge, particularly among people with high-
level fibrosis it was a source of uncertainty and increased
personal stress. These findings suggest that in this set-
ting simple and clear communication from health pro-
fessionals and education initiatives regarding TE and
liver health are required for PWID living with hepatitis
C. This may include actively employing the ‘teach-back’
technique. Developing effective and disease stage-
specific resources is crucial as it is likely to reduce
feelings of stress and anxiety for those with high-level
fibrosis and ensure treatment uptake without compla-
cency for those with low-level fibrosis.
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